Global KRAS Inhibitor Market Growth 2026-2032
The global KRAS Inhibitor market size is predicted to grow from US$ 141 million in 2025 to US$ 249 million in 2032; it is expected to grow at a CAGR of 8.6% from 2026 to 2032.
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
United States market for KRAS Inhibitor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for KRAS Inhibitor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for KRAS Inhibitor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key KRAS Inhibitor players cover Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?KRAS Inhibitor Industry Forecast? looks at past sales and reviews total world KRAS Inhibitor sales in 2025, providing a comprehensive analysis by region and market sector of projected KRAS Inhibitor sales for 2026 through 2032. With KRAS Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world KRAS Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global KRAS Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on KRAS Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global KRAS Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for KRAS Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global KRAS Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of KRAS Inhibitor market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global KRAS Inhibitor market?
What factors are driving KRAS Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do KRAS Inhibitor market opportunities vary by end market size?
How does KRAS Inhibitor break out by Type, by Application?
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
United States market for KRAS Inhibitor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for KRAS Inhibitor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for KRAS Inhibitor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key KRAS Inhibitor players cover Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?KRAS Inhibitor Industry Forecast? looks at past sales and reviews total world KRAS Inhibitor sales in 2025, providing a comprehensive analysis by region and market sector of projected KRAS Inhibitor sales for 2026 through 2032. With KRAS Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world KRAS Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global KRAS Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on KRAS Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global KRAS Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for KRAS Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global KRAS Inhibitor.
This report presents a comprehensive overview, market shares, and growth opportunities of KRAS Inhibitor market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
- Clinic Laboratories
- Cancer Diagnostic Centres
- Hospitals
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Boehringer Ingelheim
- BridgeBio Pharma
- Erasca
- Innovent Biologics
- Incyte
- Mirati Therapeutics
- Novartis
- Jemincare
- Cardiff Oncology
What is the 10-year outlook for the global KRAS Inhibitor market?
What factors are driving KRAS Inhibitor market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do KRAS Inhibitor market opportunities vary by end market size?
How does KRAS Inhibitor break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global KRAS Inhibitor Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for KRAS Inhibitor by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for KRAS Inhibitor by Country/Region, 2021, 2025 & 2032
2.2 KRAS Inhibitor Segment by Type
2.2.1 Lung Cancer
2.2.2 Pancreatic Cancer
2.2.3 Colorectal Cancer
2.2.4 Others
2.2.5 KRAS Inhibitor Sales by Type
2.2.5.1 Global KRAS Inhibitor Sales Market Share by Type (2021-2026)
2.2.5.2 Global KRAS Inhibitor Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global KRAS Inhibitor Sale Price by Type (2021-2026)
2.3 KRAS Inhibitor Segment by Application
2.3.1 Clinic Laboratories
2.3.2 Cancer Diagnostic Centres
2.3.3 Hospitals
2.3.4 Others
2.3.5 KRAS Inhibitor Sales by Application
2.3.5.1 Global KRAS Inhibitor Sale Market Share by Application (2021-2026)
2.3.5.2 Global KRAS Inhibitor Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global KRAS Inhibitor Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global KRAS Inhibitor Breakdown Data by Company
3.1.1 Global KRAS Inhibitor Annual Sales by Company (2021-2026)
3.1.2 Global KRAS Inhibitor Sales Market Share by Company (2021-2026)
3.2 Global KRAS Inhibitor Annual Revenue by Company (2021-2026)
3.2.1 Global KRAS Inhibitor Revenue by Company (2021-2026)
3.2.2 Global KRAS Inhibitor Revenue Market Share by Company (2021-2026)
3.3 Global KRAS Inhibitor Sale Price by Company
3.4 Key Manufacturers KRAS Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers KRAS Inhibitor Product Location Distribution
3.4.2 Players KRAS Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR KRAS INHIBITOR BY GEOGRAPHIC REGION
4.1 World Historic KRAS Inhibitor Market Size by Geographic Region (2021-2026)
4.1.1 Global KRAS Inhibitor Annual Sales by Geographic Region (2021-2026)
4.1.2 Global KRAS Inhibitor Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic KRAS Inhibitor Market Size by Country/Region (2021-2026)
4.2.1 Global KRAS Inhibitor Annual Sales by Country/Region (2021-2026)
4.2.2 Global KRAS Inhibitor Annual Revenue by Country/Region (2021-2026)
4.3 Americas KRAS Inhibitor Sales Growth
4.4 APAC KRAS Inhibitor Sales Growth
4.5 Europe KRAS Inhibitor Sales Growth
4.6 Middle East & Africa KRAS Inhibitor Sales Growth
5 AMERICAS
5.1 Americas KRAS Inhibitor Sales by Country
5.1.1 Americas KRAS Inhibitor Sales by Country (2021-2026)
5.1.2 Americas KRAS Inhibitor Revenue by Country (2021-2026)
5.2 Americas KRAS Inhibitor Sales by Type (2021-2026)
5.3 Americas KRAS Inhibitor Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC KRAS Inhibitor Sales by Region
6.1.1 APAC KRAS Inhibitor Sales by Region (2021-2026)
6.1.2 APAC KRAS Inhibitor Revenue by Region (2021-2026)
6.2 APAC KRAS Inhibitor Sales by Type (2021-2026)
6.3 APAC KRAS Inhibitor Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe KRAS Inhibitor by Country
7.1.1 Europe KRAS Inhibitor Sales by Country (2021-2026)
7.1.2 Europe KRAS Inhibitor Revenue by Country (2021-2026)
7.2 Europe KRAS Inhibitor Sales by Type (2021-2026)
7.3 Europe KRAS Inhibitor Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa KRAS Inhibitor by Country
8.1.1 Middle East & Africa KRAS Inhibitor Sales by Country (2021-2026)
8.1.2 Middle East & Africa KRAS Inhibitor Revenue by Country (2021-2026)
8.2 Middle East & Africa KRAS Inhibitor Sales by Type (2021-2026)
8.3 Middle East & Africa KRAS Inhibitor Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of KRAS Inhibitor
10.3 Manufacturing Process Analysis of KRAS Inhibitor
10.4 Industry Chain Structure of KRAS Inhibitor
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 KRAS Inhibitor Distributors
11.3 KRAS Inhibitor Customer
12 WORLD FORECAST REVIEW FOR KRAS INHIBITOR BY GEOGRAPHIC REGION
12.1 Global KRAS Inhibitor Market Size Forecast by Region
12.1.1 Global KRAS Inhibitor Forecast by Region (2027-2032)
12.1.2 Global KRAS Inhibitor Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global KRAS Inhibitor Forecast by Type (2027-2032)
12.7 Global KRAS Inhibitor Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen KRAS Inhibitor Product Portfolios and Specifications
13.1.3 Amgen KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim KRAS Inhibitor Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 BridgeBio Pharma
13.3.1 BridgeBio Pharma Company Information
13.3.2 BridgeBio Pharma KRAS Inhibitor Product Portfolios and Specifications
13.3.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BridgeBio Pharma Main Business Overview
13.3.5 BridgeBio Pharma Latest Developments
13.4 Erasca
13.4.1 Erasca Company Information
13.4.2 Erasca KRAS Inhibitor Product Portfolios and Specifications
13.4.3 Erasca KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Erasca Main Business Overview
13.4.5 Erasca Latest Developments
13.5 Innovent Biologics
13.5.1 Innovent Biologics Company Information
13.5.2 Innovent Biologics KRAS Inhibitor Product Portfolios and Specifications
13.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Innovent Biologics Main Business Overview
13.5.5 Innovent Biologics Latest Developments
13.6 Incyte
13.6.1 Incyte Company Information
13.6.2 Incyte KRAS Inhibitor Product Portfolios and Specifications
13.6.3 Incyte KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Incyte Main Business Overview
13.6.5 Incyte Latest Developments
13.7 Mirati Therapeutics
13.7.1 Mirati Therapeutics Company Information
13.7.2 Mirati Therapeutics KRAS Inhibitor Product Portfolios and Specifications
13.7.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mirati Therapeutics Main Business Overview
13.7.5 Mirati Therapeutics Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis KRAS Inhibitor Product Portfolios and Specifications
13.8.3 Novartis KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Jemincare
13.9.1 Jemincare Company Information
13.9.2 Jemincare KRAS Inhibitor Product Portfolios and Specifications
13.9.3 Jemincare KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Jemincare Main Business Overview
13.9.5 Jemincare Latest Developments
13.10 Cardiff Oncology
13.10.1 Cardiff Oncology Company Information
13.10.2 Cardiff Oncology KRAS Inhibitor Product Portfolios and Specifications
13.10.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Cardiff Oncology Main Business Overview
13.10.5 Cardiff Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global KRAS Inhibitor Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for KRAS Inhibitor by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for KRAS Inhibitor by Country/Region, 2021, 2025 & 2032
2.2 KRAS Inhibitor Segment by Type
2.2.1 Lung Cancer
2.2.2 Pancreatic Cancer
2.2.3 Colorectal Cancer
2.2.4 Others
2.2.5 KRAS Inhibitor Sales by Type
2.2.5.1 Global KRAS Inhibitor Sales Market Share by Type (2021-2026)
2.2.5.2 Global KRAS Inhibitor Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global KRAS Inhibitor Sale Price by Type (2021-2026)
2.3 KRAS Inhibitor Segment by Application
2.3.1 Clinic Laboratories
2.3.2 Cancer Diagnostic Centres
2.3.3 Hospitals
2.3.4 Others
2.3.5 KRAS Inhibitor Sales by Application
2.3.5.1 Global KRAS Inhibitor Sale Market Share by Application (2021-2026)
2.3.5.2 Global KRAS Inhibitor Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global KRAS Inhibitor Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global KRAS Inhibitor Breakdown Data by Company
3.1.1 Global KRAS Inhibitor Annual Sales by Company (2021-2026)
3.1.2 Global KRAS Inhibitor Sales Market Share by Company (2021-2026)
3.2 Global KRAS Inhibitor Annual Revenue by Company (2021-2026)
3.2.1 Global KRAS Inhibitor Revenue by Company (2021-2026)
3.2.2 Global KRAS Inhibitor Revenue Market Share by Company (2021-2026)
3.3 Global KRAS Inhibitor Sale Price by Company
3.4 Key Manufacturers KRAS Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers KRAS Inhibitor Product Location Distribution
3.4.2 Players KRAS Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR KRAS INHIBITOR BY GEOGRAPHIC REGION
4.1 World Historic KRAS Inhibitor Market Size by Geographic Region (2021-2026)
4.1.1 Global KRAS Inhibitor Annual Sales by Geographic Region (2021-2026)
4.1.2 Global KRAS Inhibitor Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic KRAS Inhibitor Market Size by Country/Region (2021-2026)
4.2.1 Global KRAS Inhibitor Annual Sales by Country/Region (2021-2026)
4.2.2 Global KRAS Inhibitor Annual Revenue by Country/Region (2021-2026)
4.3 Americas KRAS Inhibitor Sales Growth
4.4 APAC KRAS Inhibitor Sales Growth
4.5 Europe KRAS Inhibitor Sales Growth
4.6 Middle East & Africa KRAS Inhibitor Sales Growth
5 AMERICAS
5.1 Americas KRAS Inhibitor Sales by Country
5.1.1 Americas KRAS Inhibitor Sales by Country (2021-2026)
5.1.2 Americas KRAS Inhibitor Revenue by Country (2021-2026)
5.2 Americas KRAS Inhibitor Sales by Type (2021-2026)
5.3 Americas KRAS Inhibitor Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC KRAS Inhibitor Sales by Region
6.1.1 APAC KRAS Inhibitor Sales by Region (2021-2026)
6.1.2 APAC KRAS Inhibitor Revenue by Region (2021-2026)
6.2 APAC KRAS Inhibitor Sales by Type (2021-2026)
6.3 APAC KRAS Inhibitor Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe KRAS Inhibitor by Country
7.1.1 Europe KRAS Inhibitor Sales by Country (2021-2026)
7.1.2 Europe KRAS Inhibitor Revenue by Country (2021-2026)
7.2 Europe KRAS Inhibitor Sales by Type (2021-2026)
7.3 Europe KRAS Inhibitor Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa KRAS Inhibitor by Country
8.1.1 Middle East & Africa KRAS Inhibitor Sales by Country (2021-2026)
8.1.2 Middle East & Africa KRAS Inhibitor Revenue by Country (2021-2026)
8.2 Middle East & Africa KRAS Inhibitor Sales by Type (2021-2026)
8.3 Middle East & Africa KRAS Inhibitor Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of KRAS Inhibitor
10.3 Manufacturing Process Analysis of KRAS Inhibitor
10.4 Industry Chain Structure of KRAS Inhibitor
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 KRAS Inhibitor Distributors
11.3 KRAS Inhibitor Customer
12 WORLD FORECAST REVIEW FOR KRAS INHIBITOR BY GEOGRAPHIC REGION
12.1 Global KRAS Inhibitor Market Size Forecast by Region
12.1.1 Global KRAS Inhibitor Forecast by Region (2027-2032)
12.1.2 Global KRAS Inhibitor Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global KRAS Inhibitor Forecast by Type (2027-2032)
12.7 Global KRAS Inhibitor Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen KRAS Inhibitor Product Portfolios and Specifications
13.1.3 Amgen KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim KRAS Inhibitor Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 BridgeBio Pharma
13.3.1 BridgeBio Pharma Company Information
13.3.2 BridgeBio Pharma KRAS Inhibitor Product Portfolios and Specifications
13.3.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 BridgeBio Pharma Main Business Overview
13.3.5 BridgeBio Pharma Latest Developments
13.4 Erasca
13.4.1 Erasca Company Information
13.4.2 Erasca KRAS Inhibitor Product Portfolios and Specifications
13.4.3 Erasca KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Erasca Main Business Overview
13.4.5 Erasca Latest Developments
13.5 Innovent Biologics
13.5.1 Innovent Biologics Company Information
13.5.2 Innovent Biologics KRAS Inhibitor Product Portfolios and Specifications
13.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Innovent Biologics Main Business Overview
13.5.5 Innovent Biologics Latest Developments
13.6 Incyte
13.6.1 Incyte Company Information
13.6.2 Incyte KRAS Inhibitor Product Portfolios and Specifications
13.6.3 Incyte KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Incyte Main Business Overview
13.6.5 Incyte Latest Developments
13.7 Mirati Therapeutics
13.7.1 Mirati Therapeutics Company Information
13.7.2 Mirati Therapeutics KRAS Inhibitor Product Portfolios and Specifications
13.7.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mirati Therapeutics Main Business Overview
13.7.5 Mirati Therapeutics Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis KRAS Inhibitor Product Portfolios and Specifications
13.8.3 Novartis KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Jemincare
13.9.1 Jemincare Company Information
13.9.2 Jemincare KRAS Inhibitor Product Portfolios and Specifications
13.9.3 Jemincare KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Jemincare Main Business Overview
13.9.5 Jemincare Latest Developments
13.10 Cardiff Oncology
13.10.1 Cardiff Oncology Company Information
13.10.2 Cardiff Oncology KRAS Inhibitor Product Portfolios and Specifications
13.10.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Cardiff Oncology Main Business Overview
13.10.5 Cardiff Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. KRAS Inhibitor Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. KRAS Inhibitor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Lung Cancer
Table 4. Major Players of Pancreatic Cancer
Table 5. Major Players of Colorectal Cancer
Table 6. Major Players of Others
Table 7. Global KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 8. Global KRAS Inhibitor Sales Market Share by Type (2021-2026)
Table 9. Global KRAS Inhibitor Revenue by Type (2021-2026) & ($ million)
Table 10. Global KRAS Inhibitor Revenue Market Share by Type (2021-2026)
Table 11. Global KRAS Inhibitor Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global KRAS Inhibitor Sale by Application (2021-2026) & (K Units)
Table 13. Global KRAS Inhibitor Sale Market Share by Application (2021-2026)
Table 14. Global KRAS Inhibitor Revenue by Application (2021-2026) & ($ million)
Table 15. Global KRAS Inhibitor Revenue Market Share by Application (2021-2026)
Table 16. Global KRAS Inhibitor Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global KRAS Inhibitor Sales by Company (2021-2026) & (K Units)
Table 18. Global KRAS Inhibitor Sales Market Share by Company (2021-2026)
Table 19. Global KRAS Inhibitor Revenue by Company (2021-2026) & ($ millions)
Table 20. Global KRAS Inhibitor Revenue Market Share by Company (2021-2026)
Table 21. Global KRAS Inhibitor Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers KRAS Inhibitor Producing Area Distribution and Sales Area
Table 23. Players KRAS Inhibitor Products Offered
Table 24. KRAS Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global KRAS Inhibitor Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global KRAS Inhibitor Sales Market Share Geographic Region (2021-2026)
Table 29. Global KRAS Inhibitor Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global KRAS Inhibitor Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global KRAS Inhibitor Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global KRAS Inhibitor Sales Market Share by Country/Region (2021-2026)
Table 33. Global KRAS Inhibitor Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global KRAS Inhibitor Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas KRAS Inhibitor Sales by Country (2021-2026) & (K Units)
Table 36. Americas KRAS Inhibitor Sales Market Share by Country (2021-2026)
Table 37. Americas KRAS Inhibitor Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 39. Americas KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 40. APAC KRAS Inhibitor Sales by Region (2021-2026) & (K Units)
Table 41. APAC KRAS Inhibitor Sales Market Share by Region (2021-2026)
Table 42. APAC KRAS Inhibitor Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 44. APAC KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 45. Europe KRAS Inhibitor Sales by Country (2021-2026) & (K Units)
Table 46. Europe KRAS Inhibitor Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 48. Europe KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa KRAS Inhibitor Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa KRAS Inhibitor Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of KRAS Inhibitor
Table 54. Key Market Challenges & Risks of KRAS Inhibitor
Table 55. Key Industry Trends of KRAS Inhibitor
Table 56. KRAS Inhibitor Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. KRAS Inhibitor Distributors List
Table 59. KRAS Inhibitor Customer List
Table 60. Global KRAS Inhibitor Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global KRAS Inhibitor Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas KRAS Inhibitor Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas KRAS Inhibitor Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC KRAS Inhibitor Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC KRAS Inhibitor Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe KRAS Inhibitor Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe KRAS Inhibitor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa KRAS Inhibitor Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa KRAS Inhibitor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global KRAS Inhibitor Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global KRAS Inhibitor Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global KRAS Inhibitor Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global KRAS Inhibitor Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Amgen Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 75. Amgen KRAS Inhibitor Product Portfolios and Specifications
Table 76. Amgen KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Boehringer Ingelheim Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 80. Boehringer Ingelheim KRAS Inhibitor Product Portfolios and Specifications
Table 81. Boehringer Ingelheim KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Boehringer Ingelheim Main Business
Table 83. Boehringer Ingelheim Latest Developments
Table 84. BridgeBio Pharma Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 85. BridgeBio Pharma KRAS Inhibitor Product Portfolios and Specifications
Table 86. BridgeBio Pharma KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. BridgeBio Pharma Main Business
Table 88. BridgeBio Pharma Latest Developments
Table 89. Erasca Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 90. Erasca KRAS Inhibitor Product Portfolios and Specifications
Table 91. Erasca KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Erasca Main Business
Table 93. Erasca Latest Developments
Table 94. Innovent Biologics Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 95. Innovent Biologics KRAS Inhibitor Product Portfolios and Specifications
Table 96. Innovent Biologics KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Innovent Biologics Main Business
Table 98. Innovent Biologics Latest Developments
Table 99. Incyte Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 100. Incyte KRAS Inhibitor Product Portfolios and Specifications
Table 101. Incyte KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Incyte Main Business
Table 103. Incyte Latest Developments
Table 104. Mirati Therapeutics Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 105. Mirati Therapeutics KRAS Inhibitor Product Portfolios and Specifications
Table 106. Mirati Therapeutics KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Mirati Therapeutics Main Business
Table 108. Mirati Therapeutics Latest Developments
Table 109. Novartis Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 110. Novartis KRAS Inhibitor Product Portfolios and Specifications
Table 111. Novartis KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Novartis Main Business
Table 113. Novartis Latest Developments
Table 114. Jemincare Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 115. Jemincare KRAS Inhibitor Product Portfolios and Specifications
Table 116. Jemincare KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Jemincare Main Business
Table 118. Jemincare Latest Developments
Table 119. Cardiff Oncology Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 120. Cardiff Oncology KRAS Inhibitor Product Portfolios and Specifications
Table 121. Cardiff Oncology KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Cardiff Oncology Main Business
Table 123. Cardiff Oncology Latest Developments
Table 1. KRAS Inhibitor Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. KRAS Inhibitor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Lung Cancer
Table 4. Major Players of Pancreatic Cancer
Table 5. Major Players of Colorectal Cancer
Table 6. Major Players of Others
Table 7. Global KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 8. Global KRAS Inhibitor Sales Market Share by Type (2021-2026)
Table 9. Global KRAS Inhibitor Revenue by Type (2021-2026) & ($ million)
Table 10. Global KRAS Inhibitor Revenue Market Share by Type (2021-2026)
Table 11. Global KRAS Inhibitor Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global KRAS Inhibitor Sale by Application (2021-2026) & (K Units)
Table 13. Global KRAS Inhibitor Sale Market Share by Application (2021-2026)
Table 14. Global KRAS Inhibitor Revenue by Application (2021-2026) & ($ million)
Table 15. Global KRAS Inhibitor Revenue Market Share by Application (2021-2026)
Table 16. Global KRAS Inhibitor Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global KRAS Inhibitor Sales by Company (2021-2026) & (K Units)
Table 18. Global KRAS Inhibitor Sales Market Share by Company (2021-2026)
Table 19. Global KRAS Inhibitor Revenue by Company (2021-2026) & ($ millions)
Table 20. Global KRAS Inhibitor Revenue Market Share by Company (2021-2026)
Table 21. Global KRAS Inhibitor Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers KRAS Inhibitor Producing Area Distribution and Sales Area
Table 23. Players KRAS Inhibitor Products Offered
Table 24. KRAS Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global KRAS Inhibitor Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global KRAS Inhibitor Sales Market Share Geographic Region (2021-2026)
Table 29. Global KRAS Inhibitor Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global KRAS Inhibitor Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global KRAS Inhibitor Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global KRAS Inhibitor Sales Market Share by Country/Region (2021-2026)
Table 33. Global KRAS Inhibitor Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global KRAS Inhibitor Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas KRAS Inhibitor Sales by Country (2021-2026) & (K Units)
Table 36. Americas KRAS Inhibitor Sales Market Share by Country (2021-2026)
Table 37. Americas KRAS Inhibitor Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 39. Americas KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 40. APAC KRAS Inhibitor Sales by Region (2021-2026) & (K Units)
Table 41. APAC KRAS Inhibitor Sales Market Share by Region (2021-2026)
Table 42. APAC KRAS Inhibitor Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 44. APAC KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 45. Europe KRAS Inhibitor Sales by Country (2021-2026) & (K Units)
Table 46. Europe KRAS Inhibitor Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 48. Europe KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa KRAS Inhibitor Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa KRAS Inhibitor Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa KRAS Inhibitor Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa KRAS Inhibitor Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of KRAS Inhibitor
Table 54. Key Market Challenges & Risks of KRAS Inhibitor
Table 55. Key Industry Trends of KRAS Inhibitor
Table 56. KRAS Inhibitor Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. KRAS Inhibitor Distributors List
Table 59. KRAS Inhibitor Customer List
Table 60. Global KRAS Inhibitor Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global KRAS Inhibitor Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas KRAS Inhibitor Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas KRAS Inhibitor Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC KRAS Inhibitor Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC KRAS Inhibitor Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe KRAS Inhibitor Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe KRAS Inhibitor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa KRAS Inhibitor Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa KRAS Inhibitor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global KRAS Inhibitor Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global KRAS Inhibitor Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global KRAS Inhibitor Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global KRAS Inhibitor Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Amgen Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 75. Amgen KRAS Inhibitor Product Portfolios and Specifications
Table 76. Amgen KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Amgen Main Business
Table 78. Amgen Latest Developments
Table 79. Boehringer Ingelheim Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 80. Boehringer Ingelheim KRAS Inhibitor Product Portfolios and Specifications
Table 81. Boehringer Ingelheim KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Boehringer Ingelheim Main Business
Table 83. Boehringer Ingelheim Latest Developments
Table 84. BridgeBio Pharma Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 85. BridgeBio Pharma KRAS Inhibitor Product Portfolios and Specifications
Table 86. BridgeBio Pharma KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. BridgeBio Pharma Main Business
Table 88. BridgeBio Pharma Latest Developments
Table 89. Erasca Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 90. Erasca KRAS Inhibitor Product Portfolios and Specifications
Table 91. Erasca KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Erasca Main Business
Table 93. Erasca Latest Developments
Table 94. Innovent Biologics Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 95. Innovent Biologics KRAS Inhibitor Product Portfolios and Specifications
Table 96. Innovent Biologics KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Innovent Biologics Main Business
Table 98. Innovent Biologics Latest Developments
Table 99. Incyte Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 100. Incyte KRAS Inhibitor Product Portfolios and Specifications
Table 101. Incyte KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Incyte Main Business
Table 103. Incyte Latest Developments
Table 104. Mirati Therapeutics Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 105. Mirati Therapeutics KRAS Inhibitor Product Portfolios and Specifications
Table 106. Mirati Therapeutics KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Mirati Therapeutics Main Business
Table 108. Mirati Therapeutics Latest Developments
Table 109. Novartis Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 110. Novartis KRAS Inhibitor Product Portfolios and Specifications
Table 111. Novartis KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Novartis Main Business
Table 113. Novartis Latest Developments
Table 114. Jemincare Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 115. Jemincare KRAS Inhibitor Product Portfolios and Specifications
Table 116. Jemincare KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Jemincare Main Business
Table 118. Jemincare Latest Developments
Table 119. Cardiff Oncology Basic Information, KRAS Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 120. Cardiff Oncology KRAS Inhibitor Product Portfolios and Specifications
Table 121. Cardiff Oncology KRAS Inhibitor Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Cardiff Oncology Main Business
Table 123. Cardiff Oncology Latest Developments
LIST OF FIGURES
Figure 1. Picture of KRAS Inhibitor
Figure 2. KRAS Inhibitor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global KRAS Inhibitor Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global KRAS Inhibitor Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. KRAS Inhibitor Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. KRAS Inhibitor Sales Market Share by Country/Region (2025)
Figure 10. KRAS Inhibitor Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Lung Cancer
Figure 12. Product Picture of Pancreatic Cancer
Figure 13. Product Picture of Colorectal Cancer
Figure 14. Product Picture of Others
Figure 15. Global KRAS Inhibitor Sales Market Share by Type in 2026
Figure 16. Global KRAS Inhibitor Revenue Market Share by Type (2021-2026)
Figure 17. KRAS Inhibitor Consumed in Clinic Laboratories
Figure 18. Global KRAS Inhibitor Market: Clinic Laboratories (2021-2026) & (K Units)
Figure 19. KRAS Inhibitor Consumed in Cancer Diagnostic Centres
Figure 20. Global KRAS Inhibitor Market: Cancer Diagnostic Centres (2021-2026) & (K Units)
Figure 21. KRAS Inhibitor Consumed in Hospitals
Figure 22. Global KRAS Inhibitor Market: Hospitals (2021-2026) & (K Units)
Figure 23. KRAS Inhibitor Consumed in Others
Figure 24. Global KRAS Inhibitor Market: Others (2021-2026) & (K Units)
Figure 25. Global KRAS Inhibitor Sale Market Share by Application (2025)
Figure 26. Global KRAS Inhibitor Revenue Market Share by Application in 2026
Figure 27. KRAS Inhibitor Sales by Company in 2026 (K Units)
Figure 28. Global KRAS Inhibitor Sales Market Share by Company in 2026
Figure 29. KRAS Inhibitor Revenue by Company in 2026 ($ millions)
Figure 30. Global KRAS Inhibitor Revenue Market Share by Company in 2026
Figure 31. Global KRAS Inhibitor Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global KRAS Inhibitor Revenue Market Share by Geographic Region in 2026
Figure 33. Americas KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 34. Americas KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 35. APAC KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 36. APAC KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 37. Europe KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 38. Europe KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 41. Americas KRAS Inhibitor Sales Market Share by Country in 2026
Figure 42. Americas KRAS Inhibitor Revenue Market Share by Country (2021-2026)
Figure 43. Americas KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 44. Americas KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 45. United States KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC KRAS Inhibitor Sales Market Share by Region in 2026
Figure 50. APAC KRAS Inhibitor Revenue Market Share by Region (2021-2026)
Figure 51. APAC KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 52. APAC KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 53. China KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 57. India KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe KRAS Inhibitor Sales Market Share by Country in 2026
Figure 61. Europe KRAS Inhibitor Revenue Market Share by Country (2021-2026)
Figure 62. Europe KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 63. Europe KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 64. Germany KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 65. France KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 66. UK KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa KRAS Inhibitor Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 72. Egypt KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of KRAS Inhibitor in 2026
Figure 78. Manufacturing Process Analysis of KRAS Inhibitor
Figure 79. Industry Chain Structure of KRAS Inhibitor
Figure 80. Channels of Distribution
Figure 81. Global KRAS Inhibitor Sales Market Forecast by Region (2027-2032)
Figure 82. Global KRAS Inhibitor Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global KRAS Inhibitor Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global KRAS Inhibitor Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global KRAS Inhibitor Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global KRAS Inhibitor Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of KRAS Inhibitor
Figure 2. KRAS Inhibitor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global KRAS Inhibitor Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global KRAS Inhibitor Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. KRAS Inhibitor Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. KRAS Inhibitor Sales Market Share by Country/Region (2025)
Figure 10. KRAS Inhibitor Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Lung Cancer
Figure 12. Product Picture of Pancreatic Cancer
Figure 13. Product Picture of Colorectal Cancer
Figure 14. Product Picture of Others
Figure 15. Global KRAS Inhibitor Sales Market Share by Type in 2026
Figure 16. Global KRAS Inhibitor Revenue Market Share by Type (2021-2026)
Figure 17. KRAS Inhibitor Consumed in Clinic Laboratories
Figure 18. Global KRAS Inhibitor Market: Clinic Laboratories (2021-2026) & (K Units)
Figure 19. KRAS Inhibitor Consumed in Cancer Diagnostic Centres
Figure 20. Global KRAS Inhibitor Market: Cancer Diagnostic Centres (2021-2026) & (K Units)
Figure 21. KRAS Inhibitor Consumed in Hospitals
Figure 22. Global KRAS Inhibitor Market: Hospitals (2021-2026) & (K Units)
Figure 23. KRAS Inhibitor Consumed in Others
Figure 24. Global KRAS Inhibitor Market: Others (2021-2026) & (K Units)
Figure 25. Global KRAS Inhibitor Sale Market Share by Application (2025)
Figure 26. Global KRAS Inhibitor Revenue Market Share by Application in 2026
Figure 27. KRAS Inhibitor Sales by Company in 2026 (K Units)
Figure 28. Global KRAS Inhibitor Sales Market Share by Company in 2026
Figure 29. KRAS Inhibitor Revenue by Company in 2026 ($ millions)
Figure 30. Global KRAS Inhibitor Revenue Market Share by Company in 2026
Figure 31. Global KRAS Inhibitor Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global KRAS Inhibitor Revenue Market Share by Geographic Region in 2026
Figure 33. Americas KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 34. Americas KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 35. APAC KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 36. APAC KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 37. Europe KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 38. Europe KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa KRAS Inhibitor Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa KRAS Inhibitor Revenue 2021-2026 ($ millions)
Figure 41. Americas KRAS Inhibitor Sales Market Share by Country in 2026
Figure 42. Americas KRAS Inhibitor Revenue Market Share by Country (2021-2026)
Figure 43. Americas KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 44. Americas KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 45. United States KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC KRAS Inhibitor Sales Market Share by Region in 2026
Figure 50. APAC KRAS Inhibitor Revenue Market Share by Region (2021-2026)
Figure 51. APAC KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 52. APAC KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 53. China KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 57. India KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe KRAS Inhibitor Sales Market Share by Country in 2026
Figure 61. Europe KRAS Inhibitor Revenue Market Share by Country (2021-2026)
Figure 62. Europe KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 63. Europe KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 64. Germany KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 65. France KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 66. UK KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa KRAS Inhibitor Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa KRAS Inhibitor Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa KRAS Inhibitor Sales Market Share by Application (2021-2026)
Figure 72. Egypt KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries KRAS Inhibitor Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of KRAS Inhibitor in 2026
Figure 78. Manufacturing Process Analysis of KRAS Inhibitor
Figure 79. Industry Chain Structure of KRAS Inhibitor
Figure 80. Channels of Distribution
Figure 81. Global KRAS Inhibitor Sales Market Forecast by Region (2027-2032)
Figure 82. Global KRAS Inhibitor Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global KRAS Inhibitor Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global KRAS Inhibitor Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global KRAS Inhibitor Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global KRAS Inhibitor Revenue Market Share Forecast by Application (2027-2032)
